INT Medical to Acquire Up to 90% of Valgen Medtech for No More Than RMB1.50 Billion

Bulletin Express04-28

Shanghai INT Medical Instruments Co., Ltd. (INT Medical) has approved a resolution to pursue the acquisition of up to 90% equity in Valgen Holding Corporation, parent of Hangzhou Valgen Medtech, for a maximum consideration of RMB1.50 billion.

The proposed transaction aims to expand INT Medical’s structural heart disease portfolio and enhance its competitiveness in cardiovascular intervention. Valgen Medtech focuses on interventional therapies for atrioventricular valve diseases and has four products that have cleared China’s “green channel” for innovative medical devices, including: • MitralStitch® transapical mitral valve repair system • DragonFly™ transcatheter mitral valve clip system — the first domestically developed transcatheter mitral valve product approved for marketing in China • DragonFly-T® transcatheter tricuspid valve clip system • DragonFire® transcatheter myocardial radiofrequency ablation system

The board has authorized the chairman to finalize and sign the intent and definitive agreements within the approved price cap and stake range.

Should the deal proceed, it may constitute a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules. INT Medical will issue further announcements as required.

The company cautions shareholders and potential investors that the acquisition is still subject to negotiation and may not materialize, advising prudent decision-making when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170702151?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170702151","market":"us","top_or_hot":-1,"title":"INT Medical to Acquire Up to 90% of Valgen Medtech for No More Than RMB1.50 Billion","media":"Bulletin Express","content":"<p>Shanghai INT Medical Instruments Co., Ltd. (INT Medical) has approved a resolution to pursue the acquisition of up to 90% equity in Valgen Holding Corporation, parent of Hangzhou Valgen Medtech, for a maximum consideration of RMB1.50 billion.</p>\n<p>The proposed transaction aims to expand INT Medical’s structural heart disease portfolio and enhance its competitiveness in cardiovascular intervention. Valgen Medtech focuses on interventional therapies for atrioventricular valve diseases and has four products that have cleared China’s “green channel” for innovative medical devices, including:  \n• MitralStitch® transapical mitral valve repair system  \n• DragonFly™ transcatheter mitral valve clip system — the first domestically developed transcatheter mitral valve product approved for marketing in China  \n• DragonFly-T® transcatheter tricuspid valve clip system  \n• DragonFire® transcatheter myocardial radiofrequency ablation system</p>\n<p>The board has authorized the chairman to finalize and sign the intent and definitive agreements within the approved price cap and stake range.</p>\n<p>Should the deal proceed, it may constitute a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules. INT Medical will issue further announcements as required.</p>\n<p>The company cautions shareholders and potential investors that the acquisition is still subject to negotiation and may not materialize, advising prudent decision-making when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INT Medical to Acquire Up to 90% of Valgen Medtech for No More Than RMB1.50 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINT Medical to Acquire Up to 90% of Valgen Medtech for No More Than RMB1.50 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-28 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai INT Medical Instruments Co., Ltd. (INT Medical) has approved a resolution to pursue the acquisition of up to 90% equity in Valgen Holding Corporation, parent of Hangzhou Valgen Medtech, for a maximum consideration of RMB1.50 billion.</p>\n<p>The proposed transaction aims to expand INT Medical’s structural heart disease portfolio and enhance its competitiveness in cardiovascular intervention. Valgen Medtech focuses on interventional therapies for atrioventricular valve diseases and has four products that have cleared China’s “green channel” for innovative medical devices, including:  \n• MitralStitch® transapical mitral valve repair system  \n• DragonFly™ transcatheter mitral valve clip system — the first domestically developed transcatheter mitral valve product approved for marketing in China  \n• DragonFly-T® transcatheter tricuspid valve clip system  \n• DragonFire® transcatheter myocardial radiofrequency ablation system</p>\n<p>The board has authorized the chairman to finalize and sign the intent and definitive agreements within the approved price cap and stake range.</p>\n<p>Should the deal proceed, it may constitute a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules. INT Medical will issue further announcements as required.</p>\n<p>The company cautions shareholders and potential investors that the acquisition is still subject to negotiation and may not materialize, advising prudent decision-making when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01501","symbol_name":"瑛泰医疗","start_time":0,"source_url":"","article_id":"1170702151","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170702151","pubTimestamp":1777380285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai INT Medical Instruments Co., Ltd. (INT Medical) has approved a resolution to pursue the acquisition of up to 90% equity in Valgen Holding Corporation, parent of Hangzhou Valgen Medtech, for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01501":"瑛泰医疗"},"translate_title":"INT Medical将以不超过人民币15亿元收购Valgen Medtech最多90%股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01501":1},"content_text":"Shanghai INT Medical Instruments Co., Ltd. (INT Medical) has approved a resolution to pursue the acquisition of up to 90% equity in Valgen Holding Corporation, parent of Hangzhou Valgen Medtech, for a maximum consideration of RMB1.50 billion.\nThe proposed transaction aims to expand INT Medical’s structural heart disease portfolio and enhance its competitiveness in cardiovascular intervention. Valgen Medtech focuses on interventional therapies for atrioventricular valve diseases and has four products that have cleared China’s “green channel” for innovative medical devices, including:  \n• MitralStitch® transapical mitral valve repair system  \n• DragonFly™ transcatheter mitral valve clip system — the first domestically developed transcatheter mitral valve product approved for marketing in China  \n• DragonFly-T® transcatheter tricuspid valve clip system  \n• DragonFire® transcatheter myocardial radiofrequency ablation system\nThe board has authorized the chairman to finalize and sign the intent and definitive agreements within the approved price cap and stake range.\nShould the deal proceed, it may constitute a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules. INT Medical will issue further announcements as required.\nThe company cautions shareholders and potential investors that the acquisition is still subject to negotiation and may not materialize, advising prudent decision-making when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170702151","isCrawlerRequest":true}